Formoterol Clinical Trials

Size	Price	Qty
5mg	USD 197
25mg	USD 497

Clinical Trials

Numerous clinical trials, spanning early Phase 1 through Phase 4, evaluate formoterol as a single-agent or combination therapy for respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. These studies have been led by major pharmaceutical sponsors such as AstraZeneca and Chiesi Farmaceutici S.p.A., alongside academic centers including the University of Florida and Brigham and Women's Hospital. Across various statuses—including completed, active, recruiting, and terminated—these investigations systematically assess formoterol's safety, long-term efficacy, and airway responsiveness.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07525375	RECRUITING	Asthma	AstraZeneca	2026-04-14	PHASE2
NCT06429475	RECRUITING	Asthma	University of KwaZulu	2024-06-06	PHASE3
NCT07282886	RECRUITING	Asthma	University of Alabama at Birmingham	2026-03-15	PHASE2
NCT07546981	RECRUITING	Asthma	Chiesi Farmaceutici S.p.A.	2026-06-26	PHASE3
NCT07721922	NOT_YET_RECRUITING	COPD Exacerbation	University of Tennessee Graduate School of Medicine	2026-09-01	PHASE4
NCT06234345	NOT_YET_RECRUITING	Chronic Obstructive Pulmonary Disease	Eurofarma Laboratorios S.A.	2026-09	PHASE3
NCT07666490	RECRUITING	Asthma	Chiesi Farmaceutici S.p.A.	2026-06-28	PHASE4
NCT07768891	RECRUITING	Asthma (Diagnosis)	Lunan Better Pharmaceutical Co., LTD.	2026-06-08	PHASE3
NCT06865040	RECRUITING	Thoracic Surgery; Postoperative Pulmonary Complications (PPCs)	Centre Hospitalier Universitaire, Amiens	2025-07-31
NCT07318350	NOT_YET_RECRUITING	Moderate Asthma	Eurofarma Laboratorios S.A.	2026-10	PHASE3
NCT07595796	NOT_YET_RECRUITING	Preserved Ratio Impaired Spirometry (PRISM)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2026-06-01
NCT06283966	RECRUITING	COPD (Chronic Obstructive Pulmonary Disease)	AstraZeneca	2024-02-21	PHASE3
NCT05735431	WITHDRAWN	Moderate Asthma	Eurofarma Laboratorios S.A.	2026-06	PHASE3
NCT05111262	ACTIVE_NOT_RECRUITING	Asthma; Nonadherence, Medication	Washington University School of Medicine	2021-12-16	PHASE1; PHASE2
NCT07352488	NOT_YET_RECRUITING	Allergic Asthma	Henan University of Traditional Chinese Medicine	2026-01-15
NCT06597682	NOT_YET_RECRUITING	Post-acute Sequelae of SARS-COV-2 Infection	Huashan Hospital	2025-03
NCT06895460	NOT_YET_RECRUITING	Bronchial Asthma	The First Affiliated Hospital with Nanjing Medical University	2025-06-20	PHASE3
NCT06473779	ACTIVE_NOT_RECRUITING	Severe Asthma	AstraZeneca	2024-09-30	PHASE3
NCT06676319	ACTIVE_NOT_RECRUITING	Asthma	Sanofi	2024-11-07	PHASE2
NCT01225913	RECRUITING	Asthma	Gelb, Arthur F., M.D.	2007-10	PHASE4
NCT07073950	RECRUITING	Chronic Obstructive Pulmonary Disease; Hyperinflation	AstraZeneca	2025-11-24	PHASE4
NCT06568445	NOT_YET_RECRUITING	Bronchial Asthma	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	2024-08-12	PHASE4
NCT07133880	RECRUITING	COPD (Chronic Obstructive Pulmonary Disease)	University of Tennessee Graduate School of Medicine	2023-12-05	PHASE4
NCT07633314	SUSPENDED	Chronic Obstructive Pulmonary Disease	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2026-12	PHASE2
NCT07022418	RECRUITING	Diabetic Nephropathies; Diabetic Kidney Disease	Medical University of South Carolina	2025-12-01	PHASE2
NCT06531798	RECRUITING	Moderate to Severe COPD	AstraZeneca	2026-01-30	PHASE4
NCT07433569	COMPLETED	Asthma	AstraZeneca	2026-03-05	PHASE1
NCT06067828	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2023-10-24	PHASE3
NCT04320342	COMPLETED	COPD; COPD Exacerbation	Chiesi Farmaceutici S.p.A.	2022-04-28	PHASE3
NCT06905483	COMPLETED	COPD; Chronic Obstructive Pulmonary Disease (COPD); Small Airway Disease; Triple Therapy; Lung Function	Thammasat University	2025-04-01	PHASE4
NCT05970263	WITHDRAWN	COPD	AstraZeneca	2024-01-19	PHASE4
NCT07450482	COMPLETED	COPD (Chronic Obstructive Pulmonary Disease); COPD	Joincare Pharmaceutical Group Industry Co., Ltd	2025-07-22	PHASE2
NCT05689983	COMPLETED	Asthma in Children; Nonadherence, Medication	Washington University School of Medicine	2022-04-01	PHASE1; PHASE2
NCT06027606	COMPLETED	Healthy	University of Alberta	2023-09-01	PHASE1
NCT06590740	COMPLETED	Cough-Variant Asthma	AstraZeneca	2024-10-18	PHASE4
NCT06075095	COMPLETED	COPD (Chronic Obstructive Pulmonary Disease)	AstraZeneca	2024-01-11	PHASE3
NCT04193878	TERMINATED	Pneumonia; Hypoxemia; Acute Respiratory Failure; COVID-19 Pneumonia	Stanford University	2020-06-01	PHASE3
NCT06723756	COMPLETED	Healthy Participants	AstraZeneca	2025-01-23	PHASE1
NCT05888350	COMPLETED	Cough	The First Affiliated Hospital of Guangzhou Medical University	2023-04-01
NCT05831566	RECRUITING	Asthma	Franciscus Gasthuis	2023-01-31	PHASE3
NCT02500784	WITHDRAWN	Alzheimer's Disease; Cognitive Dysfunction	Palo Alto Veterans Institute for Research	2023-01	PHASE2
NCT06340581	WITHDRAWN	Healthy	AstraZeneca	2024-10-17	PHASE1
NCT05202262	COMPLETED	Asthma	AstraZeneca	2022-01-12	PHASE3
NCT06282861	TERMINATED	Chronic Obstructive Pulmonary Disease	Fundacio Privada Mon Clinic Barcelona	2024-02-29	PHASE4
NCT06571942	UNKNOWN	COPD Bronchitis; Pollution Related Respiratory Disorder	National Institute of Respiratory Diseases, Mexico	2023-11-15	PHASE4
NCT05755906	COMPLETED	Asthma	AstraZeneca	2023-02-27	PHASE3
NCT04233190	COMPLETED	Asthma Copd	Eurofarma Laboratorios S.A.	2023-04-19	PHASE3
NCT07790159	COMPLETED	Asthma	Shanghai Xin Huanghe Pharmaceutical Co., Ltd.	2024-02-21	PHASE3
NCT06105671	COMPLETED	Exercise Performance	Morten Hostrup, PhD	2024-01-05
NCT05292586	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2022-08-31	PHASE3
NCT06297668	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2024-04-29	PHASE1
NCT05018598	TERMINATED	Asthma	Chiesi Farmaceutici S.p.A.	2022-02-25	PHASE4
NCT05573464	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2022-09-27	PHASE3
NCT07804303	COMPLETED	Asthma; Chronic Obstructive Pulmonary Disease (COPD)	Shanghai Xin Huanghe Pharmaceutical Co., Ltd.	2024-01-13	PHASE1
NCT06869382	COMPLETED	Asthma Patients	Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	2023-01-01	PHASE4
NCT05322707	COMPLETED	Asthma	Cipla Ltd.	2022-04-15	PHASE3
NCT05898984	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2023-04-24	PHASE1
NCT04191447	UNKNOWN	Asthma	EMS	2022-07-22	PHASE3
NCT05553184	COMPLETED	Type 2 Diabetes; Obesity	Université de Sherbrooke	2022-07-05
NCT04191434	UNKNOWN	Asthma	EMS	2022-07-22	PHASE3
NCT05569421	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2022-10-11	PHASE1
NCT05477108	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2022-07-29	PHASE1
NCT04087590	TERMINATED	Copd	University Hospital, Lille	2020-01-14	PHASE2
NCT05097014	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2021-10-28	PHASE4
NCT04737655	UNKNOWN	COPD Exacerbation	PARZIBUT Gilles	2021-02-15	PHASE4
NCT04886999	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2022-02-24	PHASE3
NCT04675463	UNKNOWN	Pulmonary Disease, Chronic Obstructive	ShiYue Li	2020-12-30
NCT04655170	COMPLETED	COPD Exacerbation	University of Tennessee Graduate School of Medicine	2020-12-09	PHASE4
NCT04616261	UNKNOWN	Healthy	University of Copenhagen	2020-11-10
NCT03846570	TERMINATED	Bronchiectasis	Erasmus Medical Center	2019-01-29	PHASE3
NCT03888131	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2018-07-30	PHASE3
NCT06657066	COMPLETED	Asthma Patients	King Edward Medical University	2021-12-06	PHASE2; PHASE3
NCT03022097	COMPLETED	COPD	AstraZeneca	2017-02-02	PHASE3
NCT03083067	COMPLETED	COPD Exacerbation; Air Pollution	Peking University First Hospital	2017-03-20
NCT04876677	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2021-05-18	PHASE3
NCT04671355	WITHDRAWN	COPD	Chiesi Farmaceutici S.p.A.	2021-10-04	PHASE4
NCT04937543	COMPLETED	Covid19	UPECLIN HC FM Botucatu Unesp	2021-06-28	PHASE2
NCT04215848	COMPLETED	Asthma	Hat Yai Medical Education Center	2020-04-01	PHASE3
NCT04705727	TERMINATED	Asthma in Children	Centre Hospitalier Intercommunal Creteil	2021-08-23	PHASE3
NCT03565302	UNKNOWN	Hypertrophy; Physiologic Hypertrophy; Physical Activity	Morten Hostrup, PhD	2018-06-25
NCT04271839	WITHDRAWN	Persistent Asthma	Mundipharma Pharmaceuticals S.L.	2020-06-11	PHASE4
NCT02833480	UNKNOWN	Chronic Obstructive Pulmonary Disease	University of British Columbia	2015-02	PHASE2
NCT04078126	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2019-09-10	PHASE3
NCT04171180	UNKNOWN	Cough Variant Asthma	Second Affiliated Hospital, Zhejiang University, School of Medicine	2020-05-01	PHASE4
NCT04137029	UNKNOWN	Health, Subjective; Hyperreactivity, Bronchial	Federal State Budgetary Institution, Pulmonology Scientific Research Institute	2019-04-24
NCT03197818	COMPLETED	COPD (Chronic Obstructive Pulmonary Disease)	Chiesi Farmaceutici S.p.A.	2016-12-14	PHASE3
NCT04331470	UNKNOWN	COVID-19	Fasa University of Medical Sciences	2020-04-04	PHASE2; PHASE3
NCT03795350	TERMINATED	Chronic Obstructive Pulmonary Disease; Asthma	Chiesi Farmaceutici S.p.A.	2019-01-14	PHASE1
NCT03275116	UNKNOWN	Chronic Obstructive Airway Disease	Maastricht University Medical Center	2017-07-07	PHASE4
NCT03906045	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2019-04-04	PHASE1
NCT04520230	COMPLETED	COPD	Tanta University	2014-10-31	PHASE4
NCT03387241	UNKNOWN	Asthma	Mundipharma (China) Pharmaceutical Co. Ltd	2017-06-02	PHASE3
NCT03324607	COMPLETED	COPD	Bastiaan Driehuys	2018-04-20	PHASE2; PHASE3
NCT03836677	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2019-02-26	PHASE3
NCT03842904	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Medicines Evaluation Unit Ltd	2018-12-13	PHASE4
NCT02972476	COMPLETED	Chronic Obstructive Pulmonary Disease	University of Dundee	2016-12	PHASE4
NCT02477397	UNKNOWN	COPD	University Medical Center Groningen	2015-05-01	PHASE3
NCT03478696	COMPLETED	Pulmonary Disease, Chronic Obstructive	GlaxoSmithKline	2018-06-25	PHASE4
NCT03478683	COMPLETED	Pulmonary Disease, Chronic Obstructive	GlaxoSmithKline	2018-06-25	PHASE4
NCT03268226	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2017-11-20	PHASE3
NCT03081156	COMPLETED	Pulmonary Disease, Chronic Obstructive	William Stringer, md	2017-03-27	PHASE4
NCT03181880	WITHDRAWN	Chronic Obstructive Pulmonary Disease	AstraZeneca	2017-12-04	PHASE4
NCT03104634	COMPLETED	Smoking	McGill University Health Centre/Research Institute of the McGill University Health Centre	2017-05-01	PHASE3
NCT03504527	UNKNOWN	Asthma-COPD Overlap	Huashan Hospital	2018-05-01
NCT03740373	COMPLETED	Pulmonary Disease, Chronic Obstructive	AstraZeneca	2018-09-04	PHASE1
NCT03573817	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Mylan Inc.	2018-05-31	PHASE3
NCT03551197	UNKNOWN	Pulmonary Disease, Chronic Obstructive; Exercise; Lung Function Decreased; Quality of Life	Zhujiang Hospital	2018-06-13	PHASE4
NCT03563001	UNKNOWN	Pulmonary Disease, Chronic Obstructive; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Small Airway Disease; Quality of Life	Zhujiang Hospital	2018-06-20	PHASE4
NCT03258749	UNKNOWN	Chronic Obstructive Pulmonary Disease	Huashan Hospital	2017-11-01
NCT02429765	COMPLETED	COPD	Queen's University	2015-10	PHASE4
NCT03086460	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2017-09-08	PHASE2
NCT03276078	COMPLETED	Pulmonary Disease, Chronic Obstructive	AstraZeneca	2017-11-23	PHASE2
NCT02495168	COMPLETED	Asthma	Actavis Inc.	2017-01-13	PHASE3
NCT02676089	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2016-04-06	PHASE3
NCT02676076	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2016-02-17	PHASE3
NCT03162055	COMPLETED	Chronic Obstructive Pulmonary Disease COPD	AstraZeneca	2017-05-25	PHASE3
NCT03015259	COMPLETED	Asthma	Kindeva Drug Delivery	2016-12-29	PHASE3
NCT02573233	COMPLETED	Asthma	Sanofi	2016-01-27	PHASE2
NCT02741271	COMPLETED	Asthma	Organon and Co	2016-05-11	PHASE3
NCT02757209	COMPLETED	Asthma; COPD	Consorzio Futuro in Ricerca	2016-04
NCT04494321	COMPLETED	Asthma; COPD	Intech Biopharm Ltd.	2017-06-19	PHASE1
NCT02224157	COMPLETED	Asthma	AstraZeneca	2014-11-28	PHASE3
NCT02753712	COMPLETED	Asthma	Mundipharma Research Limited	2016-06-15	PHASE3
NCT02149199	COMPLETED	Asthma	AstraZeneca	2014-07-07	PHASE3
NCT02988869	COMPLETED	COPD	Neutec Ar-Ge San ve Tic A.Ş	2016-08	PHASE4
NCT02446418	COMPLETED	Asthma	GlaxoSmithKline	2015-07-09	PHASE3
NCT02796677	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2016-07-05	PHASE3
NCT02787967	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2016-08	PHASE2
NCT02491970	TERMINATED	Asthma	Mundipharma Korea Ltd	2015-08-31	PHASE4
NCT02975843	COMPLETED	Chronic Obstructive Pulmonary Disease; Asthma	Chiesi Farmaceutici S.p.A.	2016-11-21	PHASE1
NCT03028701	COMPLETED	Copd	Neutec Ar-Ge San ve Tic A.Ş	2015-09	PHASE4
NCT02934945	UNKNOWN	Bronchial Asthma	Zhujiang Hospital	2015-09	PHASE4
NCT02467452	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2015-05	PHASE3
NCT02796651	COMPLETED	Chronic Obstructive Pulmonary Disease - COPD	AstraZeneca	2016-06-30	PHASE2
NCT02725242	COMPLETED	Asthma	Hat Yai Medical Education Center	2016-03	PHASE3
NCT01471340	COMPLETED	Asthma	Organon and Co	2012-01-09	PHASE4
NCT02693769	TERMINATED	ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)	Mundipharma Research Limited	2016-07	PHASE2; PHASE3
NCT02275481	TERMINATED	Chronic Obstructive Pulmonary Disease (COPD)	Sumitomo Pharma America, Inc.	2014-11	PHASE4
NCT02533505	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2015-08-25	PHASE4
NCT02424344	COMPLETED	Pulmonary Disease, Chronic Obstructive	AstraZeneca	2015-04-27	PHASE4
NCT01656005	COMPLETED	Chronic Obstructive Pulmonary Disease	University of Dundee	2012-08	PHASE4
NCT02574975	UNKNOWN	Asthma	Zhujiang Hospital	2015-04	PHASE4
NCT01845025	TERMINATED	Persistent Asthma	Novartis Pharmaceuticals	2013-05	PHASE4
NCT02526758	UNKNOWN	Pulmonary Disease，Chronic Obstructive;	Zhujiang Hospital	2015-04	PHASE4
NCT02850484	COMPLETED	Asthma; Chronic Obstructive Pulmonary Disease (COPD)	Intech Biopharm Ltd.	2016-03	PHASE1
NCT02195375	COMPLETED	Chronic Obstructive Pulmonary Disease	Mundipharma Research Limited	2014-09	PHASE2; PHASE3
NCT02345161	COMPLETED	Pulmonary Disease, Chronic Obstructive	GlaxoSmithKline	2015-01-23	PHASE3
NCT01946620	COMPLETED	Chronic Obstructive Pulmonary Disease	Mundipharma Research Limited	2013-10	PHASE3
NCT01911364	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2014-01	PHASE3
NCT02291016	COMPLETED	COPD Exacerbation	University of Tennessee Graduate School of Medicine	2015-02
NCT03073057	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2016-01	PHASE1
NCT02157935	COMPLETED	COPD Patients	AstraZeneca	2014-06-27	PHASE3
NCT02388373	COMPLETED	Asthma	Research in Real-Life Ltd	2014-07	PHASE4
NCT02415179	COMPLETED	Asthma	Mahidol University	2015-05
NCT01917331	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Chiesi Farmaceutici S.p.A.	2014-03-21	PHASE3
NCT01488019	COMPLETED	COPD	Dey	2012-03	PHASE4
NCT01658891	WITHDRAWN	Asthma in Children	Chiesi Farmaceutici S.p.A.	2014-02	PHASE3
NCT01444430	COMPLETED	Asthma	AstraZeneca	2011-12	PHASE3
NCT01253473	COMPLETED	Pulmonary Disease, Chronic Obstructive	National Jewish Health	2012-04	PHASE4
NCT01912872	TERMINATED	Severe IgE-mediated Asthma	Novartis Pharmaceuticals	2013-11-11	PHASE4
NCT01783821	COMPLETED	Acute Respiratory Distress Syndrome (ARDS)	Mayo Clinic	2013-07	PHASE2
NCT01853787	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	University of Milan	2014-07	PHASE4
NCT02308098	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2014-12	PHASE3
NCT01794780	COMPLETED	COPD	Novartis Pharmaceuticals	2013-02-05	PHASE4
NCT01836016	UNKNOWN	Pulmonary Disease, Chronic Obstructive	Henan University of Traditional Chinese Medicine	2013-05	PHASE3
NCT02345993	UNKNOWN	Asthma; Asthmatic Crisis	National Institute of Respiratory Diseases, Mexico	2015-01	PHASE4
NCT02040597	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Chiesi Farmaceutici S.p.A.	2014-01	PHASE1
NCT02062463	COMPLETED	Asthma	Teva Branded Pharmaceutical Products R&D, Inc.	2014-05-28	PHASE3
NCT02127866	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2014-04-11	PHASE2
NCT02119234	COMPLETED	COPD	Chiesi Farmaceutici S.p.A.	2014-03	PHASE1
NCT02268396	COMPLETED	COPD	Pearl Therapeutics, Inc.	2014-11	PHASE3
NCT01787097	COMPLETED	Chronic Obstructive Lung Disease	Imperial College London	2013-01	PHASE4
NCT01892787	COMPLETED	Asthma	University of Dundee	2013-07	PHASE4
NCT01466712	UNKNOWN	COPD; Emphysema; Small Airway Disease	KU Leuven	2011-11	PHASE4
NCT02403713	COMPLETED	Asthma	Mundipharma Research Limited	2014-08	PHASE1
NCT02148120	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2014-04	PHASE2
NCT02196714	COMPLETED	COPD	Pearl Therapeutics, Inc.	2014-07	PHASE1
NCT01769898	COMPLETED	Bronchiectasis	The First Affiliated Hospital of Guangzhou Medical University	2013-07	PHASE4
NCT01908140	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2013-09	PHASE3
NCT01194479	COMPLETED	Type 1 Diabetes	Yale University	2010-08
NCT02000609	COMPLETED	COPD	Chiesi Farmaceutici S.p.A.	2013-12	PHASE2
NCT01602523	UNKNOWN	Emphysema; Poor Sleep Quality	Temple University	2011-03	PHASE3
NCT01070888	TERMINATED	Exercise Induced Asthma	Boston Children's Hospital	2010-02	PHASE4
NCT01803555	COMPLETED	Asthma	Teva Branded Pharmaceutical Products R&D, Inc.	2013-07-04	PHASE3
NCT01570478	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2012-07	PHASE3
NCT00961155	UNKNOWN	Asthma	Medical University of Lodz	2009-08	PHASE2
NCT01980615	COMPLETED	Healthy Volunteers	Pearl Therapeutics, Inc.	2013-11	PHASE1
NCT01450774	COMPLETED	Childhood Asthma	Chiesi Farmaceutici S.p.A.	2011-09	PHASE3
NCT01117116	COMPLETED	Asthma	National Jewish Health	2010-03
NCT01615874	WITHDRAWN	Asthma	Organon and Co	2013-01	PHASE2
NCT01290874	COMPLETED	Asthma	Brigham and Women's Hospital	2011-03-30	PHASE3
NCT01361984	UNKNOWN	Chronic Obstructive Pulmonary Disease; COPD; Emphysema; Chronic Bronchitis	University of California, Los Angeles	2011-06	PHASE4
NCT01397890	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2011-07	PHASE4
NCT01650441	COMPLETED	Asthma	University Hospital, Antwerp	2012-04	PHASE2
NCT01572792	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2012-04	PHASE3
NCT01453881	COMPLETED	Asthma	Universidade Federal de Pernambuco	2011-04	PHASE3
NCT01574651	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Novartis Pharmaceuticals	2012-05	PHASE3
NCT01748279	COMPLETED	COPD	Medical University of Bialystok	2012-12	PHASE4
NCT01555099	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2012-04	PHASE2
NCT00849095	COMPLETED	Asthma	Università degli Studi di Ferrara	2009-04	PHASE3
NCT01437540	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2011-09-19	PHASE3
NCT01437397	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2011-09	PHASE3
NCT01641081	COMPLETED	Asthma	AstraZeneca	2012-06	PHASE2
NCT01584492	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2011-12	PHASE2
NCT01738087	COMPLETED	Asthmatic	Chiesi Farmaceutici S.p.A.	2012-11	PHASE2
NCT01462942	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2011-10	PHASE3
NCT01415518	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2011-09-01	PHASE4
NCT01351792	TERMINATED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2011-09	PHASE3
NCT01668121	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2012-08	PHASE1
NCT01711086	UNKNOWN	Asthma	Guy Steuer	2012-10	PHASE1; PHASE2
NCT01202084	COMPLETED	Asthma	Eurofarma Laboratorios S.A.	2012-01	PHASE3
NCT01627158	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2012-06	PHASE1
NCT01391559	COMPLETED	Chronic Obstructive Pulmonary Disease	Dartmouth-Hitchcock Medical Center	2011-07
NCT01593826	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2012-05	PHASE1
NCT01803087	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2012-02	PHASE2
NCT01344655	COMPLETED	Pulmonary Disease, Chronic Obstructive	Chiesi Farmaceutici S.p.A.	2011-04	PHASE4
NCT01476813	COMPLETED	Pulmonary Disease, Chronic Obstructive	Chiesi Farmaceutici S.p.A.	2012-03	PHASE2
NCT01475032	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2011-09	PHASE3
NCT01566149	COMPLETED	Asthma	Organon and Co	2012-03	PHASE3
NCT01468272	COMPLETED	Asthma in Children	Chiesi Farmaceutici S.p.A.	2011-11	PHASE2
NCT01360021	COMPLETED	Asthma	AstraZeneca	2011-11	PHASE3
NCT01393145	WITHDRAWN	Chronic Obstructive Pulmonary Disease; COPD	Ache Laboratorios Farmaceuticos S.A.	2011-08	PHASE3
NCT00624754	COMPLETED	Obstructive Airway Disease	Assistance Publique - Hôpitaux de Paris	2008-03	PHASE2
NCT01760304	TERMINATED	Chronic Obstructive Pulmonary Disease (COPD)	Brigham and Women's Hospital	2012-01	PHASE4
NCT01560689	COMPLETED	Bronchiolitis Obliterans; Allogeneic Stem Cell Transplantation	Assistance Publique - Hôpitaux de Paris	2008-06	PHASE2
NCT01257048	COMPLETED	COPD Method Evaluation; Chronic Obstructive Pulmonary Disease Method Evaluation	AstraZeneca	2011-08	EARLY_PHASE1
NCT00909779	COMPLETED	Chronic Obstructive Pulmonary Disease	Sumitomo Pharma America, Inc.	2009-06	PHASE3
NCT01245569	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2011-04-12	PHASE3
NCT01204034	COMPLETED	Chronic Obstructive Pulmonary Disease	University Hospital, Antwerp	2010-09	PHASE3
NCT01551888	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2012-01	PHASE2
NCT00929851	COMPLETED	Pulmonary Disease, Chronic Obstructive	Chiesi Farmaceutici S.p.A.	2009-10	PHASE3
NCT01377428	WITHDRAWN	Chronic Obstructive Pulmonary Disease (COPD)	Novartis Pharmaceuticals	2011-09	PHASE4
NCT01136655	COMPLETED	Asthma	AstraZeneca	2010-09	PHASE2
NCT01349803	COMPLETED	Chronic Obstructive Pulmonary Disease	Pearl Therapeutics, Inc.	2011-05	PHASE2
NCT01386996	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2011-07	PHASE1
NCT01457716	COMPLETED	Healthy	Orion Corporation, Orion Pharma	2011-10
NCT01070784	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2010-01	PHASE3
NCT01179152	UNKNOWN	Asthma Exacerbation	Meir Medical Center	2010-09
NCT01258803	COMPLETED	Asthma	Organon and Co	2010-12	PHASE2
NCT01423305	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2011-08	PHASE1
NCT01191424	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2010-10	PHASE2
NCT01398111	COMPLETED	COPD	Chiesi Farmaceutici S.p.A.	2011-05	PHASE1
NCT01167010	COMPLETED	Asthma	Eurofarma Laboratorios S.A.	2011-04	PHASE3
NCT01349868	COMPLETED	Chronic Obstructive Pulmonary Disease	Pearl Therapeutics, Inc.	2011-05	PHASE2
NCT01256086	COMPLETED	Asthma	MEDA Pharma GmbH & Co. KG	2010-12	PHASE2
NCT01349257	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2011-05	PHASE2
NCT00846287	COMPLETED	Chronic Obstructive Pulmonary Disease	University of Massachusetts, Worcester	2008-11
NCT01001364	COMPLETED	ASTHMA	Eurofarma Laboratorios S.A.	2010-02	PHASE3
NCT01043601	WITHDRAWN	COPD	Pearl Therapeutics, Inc.	2010-07	PHASE2
NCT01069289	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2010-01	PHASE3
NCT01013753	COMPLETED	Asthma	Boehringer Ingelheim	2010-02	PHASE2
NCT01047553	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2009-12	PHASE3
NCT00861926	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2009-03-20	PHASE3
NCT00793624	COMPLETED	Pulmonary Disease, Chronic Obstructive	Boehringer Ingelheim	2009-02	PHASE3
NCT00796653	COMPLETED	Pulmonary Disease, Chronic Obstructive	Boehringer Ingelheim	2009-01	PHASE3
NCT01848769	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2009-09	PHASE2
NCT00914654	UNKNOWN	Asthma	Bispebjerg Hospital	2009-07	PHASE4
NCT01329276	COMPLETED	Chronic Obstructive Pulmonary Disease	University Hospital, Antwerp	2010-06	PHASE4
NCT01085045	COMPLETED	Chronic Obstructive Pulmonary Disease	Pearl Therapeutics, Inc.	2010-03	PHASE2
NCT01181063	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2010-08	PHASE1
NCT01176747	COMPLETED	Pulmonary Disease, Chronic Obstructive; Asthma	Chiesi Farmaceutici S.p.A.	2010-08	PHASE1; PHASE2
NCT00901368	COMPLETED	Asthmatic Patients	Chiesi Farmaceutici S.p.A.	2009-05	PHASE4
NCT01676987	COMPLETED	Asthma	Ache Laboratorios Farmaceuticos S.A.	2009-04	PHASE3
NCT01078623	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2010-02	PHASE2
NCT00910793	COMPLETED	Asthma	Wilfried De Backer	2008-08	PHASE4
NCT01120093	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2010-05	PHASE2
NCT01049360	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2009-12	PHASE2
NCT01168310	COMPLETED	Chronic Obstructive Pulmonary Disease	Dey	2010-08	PHASE2
NCT01023516	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2009-11	PHASE2
NCT00939341	COMPLETED	Asthma	AstraZeneca	2009-07	PHASE4
NCT00997477	WITHDRAWN	Asthma	Novartis Pharmaceuticals	2010-06	PHASE4
NCT00995800	COMPLETED	Asthma	Mundipharma Research Limited	2009-10	PHASE2
NCT00383435	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Organon and Co	2006-10	PHASE3
NCT00989833	COMPLETED	Exercise Induced Asthma	AstraZeneca	2009-09	PHASE2
NCT00383721	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Organon and Co	2006-09	PHASE3
NCT00706446	TERMINATED	Asthma	Brigham and Women's Hospital	2008-06
NCT00900874	UNKNOWN	Bronchial Asthma	All India Institute of Medical Sciences	2009-01	PHASE4
NCT01113593	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	Dey	2010-05	PHASE2
NCT01048333	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2010-01	PHASE2
NCT01186653	COMPLETED	Chronic Obstructive Pulmonary Disease	Hull University Teaching Hospitals NHS Trust	2007-10	PHASE4
NCT00929708	COMPLETED	COPD	AstraZeneca	2009-06	PHASE2
NCT00497237	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2007-04	PHASE3
NCT00964535	COMPLETED	Asthma	Orion Corporation, Orion Pharma	2009-09	PHASE1; PHASE2
NCT00419952	COMPLETED	Asthma	AstraZeneca	2007-02	PHASE3
NCT00819637	TERMINATED	Acute Asthma	Henry Ford Health System	2009-01	PHASE4
NCT00862394	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2009-02	PHASE3
NCT00702325	COMPLETED	Asthma	AstraZeneca	2008-06	PHASE4
NCT00419744	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2007-01	PHASE3
NCT00868023	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2009-02	PHASE2
NCT00734318	COMPLETED	Asthma, Bronchial	Mundipharma Research Limited	2008-09	PHASE3
NCT00635882	COMPLETED	Asthma; Airway Inflammation	Organon and Co	2008-02	PHASE2
NCT00868426	COMPLETED	Healthy	Orion Corporation, Orion Pharma	2009-04	PHASE1
NCT00773786	COMPLETED	COPD	Trinity Health Of New England	2008-10	PHASE4
NCT00754546	COMPLETED	Chronic Obstructive Pulmonary Disease	Dartmouth-Hitchcock Medical Center	2008-08	PHASE4
NCT00880490	COMPLETED	Chronic Obstructive Pulmonary Disease	Pearl Therapeutics, Inc.	2008-11	PHASE1; PHASE2
NCT00774761	COMPLETED	Chronic Obstructive Pulmonary Disease	Dey	2008-11	PHASE2
NCT00746330	COMPLETED	Asthma	Novartis	2008-08	PHASE2
NCT00628862	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2007-12	PHASE3
NCT00662779	WITHDRAWN	Exercise-induced Bronchospasm	University of New Mexico	2008-04	PHASE3
NCT00633776	WITHDRAWN	Chronic Obstructive Pulmonary Disease; COPD; Chronic Bronchitis; Emphysema	University of California, Los Angeles	2008-03	PHASE4
NCT00643578	COMPLETED	Asthma	University of Florida	2008-03
NCT00680056	COMPLETED	Pulmonary Disease, Chronic Obstructive; Chronic Bronchitis; Pulmonary Emphysema	Federal University of São Paulo	2007-11	PHASE4
NCT00633919	COMPLETED	Allergy	ALK-Abelló A/S	2006-07	PHASE2; PHASE3
NCT00583947	COMPLETED	Asthma	Sumitomo Pharma America, Inc.	2008-01	PHASE2
NCT00736489	COMPLETED	Asthma; Airway Obstruction	AstraZeneca	2008-08	PHASE2
NCT01255579	COMPLETED	Bronchial Asthma	Università degli Studi di Brescia	2007-07	PHASE4
NCT00569712	COMPLETED	Lung Cancer; Precancerous Condition	British Columbia Cancer Agency	2007-01	PHASE1
NCT00850265	COMPLETED	Asthma	Hospital General de Requena	2008-03
NCT00706914	TERMINATED	Pulmonary Disease, Chronic Obstructive	AstraZeneca	2008-06-30	PHASE2
NCT00604500	COMPLETED	Asthma; COPD	Organon and Co	2008-03-01	PHASE3
NCT00424008	COMPLETED	Asthma	Organon and Co	2007-04	PHASE3
NCT00626522	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2008-02	PHASE2
NCT00649025	COMPLETED	Asthma	SkyePharma AG	2008-03	PHASE3
NCT00383240	COMPLETED	Asthma	Organon and Co	2006-09	PHASE3
NCT00734292	COMPLETED	Mild to Moderate Asthma	SkyePharma AG	2008-09	PHASE2
NCT00996697	COMPLETED	COPD	Brian J Lipworth	2006-10	PHASE4
NCT00460577	COMPLETED	Acute Bronchial Obstruction, Asthma	Novartis	2007-03	PHASE4
NCT01343745	COMPLETED	Mild Persistent Asthma	Chiesi Farmaceutici S.p.A.	2008-02	PHASE2
NCT00542880	COMPLETED	Chronic Obstructive Pulmonary Disease (COPD)	AstraZeneca	2007-09	PHASE4
NCT00489853	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2007-07	PHASE4
NCT00463567	COMPLETED	Pulmonary Disease, Chronic Obstructive; COPD; Lung Diseases, Obstructive	Novartis	2007-04	PHASE2; PHASE3
NCT00383552	COMPLETED	Asthma	Organon and Co	2006-09	PHASE3
NCT00476099	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2006-12	PHASE3
NCT00393458	COMPLETED	Chronic Obstructive Pulmonary Disease	Novartis	2006-10	PHASE3
NCT00419757	COMPLETED	Asthma	AstraZeneca	2007-01	PHASE3
NCT00496470	COMPLETED	Chronic Obstructive Pulmonary Disease, COPD	AstraZeneca	2007-05	PHASE4
NCT00557466	COMPLETED	COPD	Novartis	2007-10	PHASE2
NCT00545272	COMPLETED	Asthma	Novartis Pharmaceuticals	2007-10	PHASE2
NCT00393952	COMPLETED	Asthma	SkyePharma AG	2006-06	PHASE3
NCT00393991	COMPLETED	Asthma	SkyePharma AG	2006-07	PHASE3
NCT00563056	COMPLETED	Asthma Bronchiale	Mundipharma Research Limited	2007-09	PHASE3
NCT00571428	COMPLETED	Chronic Obstructive Pulmonary Disease	Sumitomo Pharma America, Inc.	2007-11	PHASE4
NCT00475813	COMPLETED	Asthma	Mundipharma Research Limited	2007-03	PHASE3
NCT00536913	COMPLETED	Asthma	AstraZeneca	2007-09	PHASE3
NCT00394199	COMPLETED	Asthma	SkyePharma AG	2006-06	PHASE3
NCT00381485	COMPLETED	Asthma	Organon and Co	2006-07-01	PHASE3
NCT00476073	COMPLETED	Asthma Bronchiale	Mundipharma Research Limited	2007-04	PHASE3
NCT00379288	COMPLETED	Asthma	Organon and Co	2006-06	PHASE3
NCT00424528	COMPLETED	Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema	Sumitomo Pharma America, Inc.	2006-12	PHASE4
NCT00250679	COMPLETED	Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema	Sumitomo Pharma America, Inc.	2005-10	PHASE3
NCT00507234	COMPLETED	Chronic Obstructive Pulmonary Disease	Dey	2007-03	PHASE3
NCT00462540	COMPLETED	Chronic Obstructive Pulmonary Disease	Dey	2007-05	PHASE3
NCT00394121	COMPLETED	Asthma	SkyePharma AG	2006-03	PHASE3
NCT00443482	COMPLETED	Asthma	Novartis	2007-02	PHASE2
NCT00403286	COMPLETED	Chronic Obstructive Pulmonary Disease	Dey	2006-11	PHASE2
NCT00403637	COMPLETED	Asthma	Novartis	2006-11	PHASE2; PHASE3
NCT01280175	COMPLETED	Healthy Volunteers	Chiesi Farmaceutici S.p.A.	2006-12	PHASE1
NCT00396604	COMPLETED	Pulmonary Disease, Chronic Obstructive; COPD; Lung Diseases, Obstructive	Novartis	2006-10	PHASE2; PHASE3
NCT00255255	COMPLETED	Asthma	AstraZeneca	2005-11	PHASE3
NCT00139932	COMPLETED	Pulmonary Disease, Chronic Obstructive	Merck Sharp & Dohme LLC	2005-09-01	PHASE4
NCT00159263	COMPLETED	Asthma	Imperial College London	2004-11
NCT00235911	COMPLETED	Asthma	AstraZeneca	2003-09	PHASE3
NCT00242411	COMPLETED	Asthma	AstraZeneca	2004-09	PHASE4
NCT00280371	COMPLETED	COPD	Dey	2006-01	PHASE3
NCT00308191	COMPLETED	COPD	Dey	2006-04	PHASE3
NCT00972140	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2005-08	PHASE3
NCT00314509	COMPLETED	Asthma	AstraZeneca	2005-07	PHASE2
NCT00215449	COMPLETED	COPD	Dey		PHASE3
NCT00134979	COMPLETED	Chronic Obstructive Pulmonary Disease	Novartis Pharmaceuticals	2004-10	PHASE4
NCT00238784	COMPLETED	Asthma	AstraZeneca	2004-05	PHASE3
NCT00685529	COMPLETED	COPD	Sumitomo Pharma America, Inc.	2005-04	PHASE2
NCT00215436	COMPLETED	COPD	Dey	2005-03	PHASE3
NCT00413387	COMPLETED	Bronchial Asthma	Chiesi Farmaceutici S.p.A.	2004-09	PHASE3
NCT00130351	COMPLETED	Asthma	Novartis	2005-07	PHASE3
NCT00742248	COMPLETED	Chronic Obstructive Pulmonary Disease	Chiesi Farmaceutici S.p.A.	2004-09	PHASE2
NCT00728715	COMPLETED	Bronchiectasis	Hospital General de Requena	2004-01
NCT00830102	COMPLETED	Asthma	SkyePharma AG	2004-10	PHASE2
NCT00476268	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2004-02	PHASE3
NCT00064415	COMPLETED	Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema	Sumitomo Pharma America, Inc.	2002-06	PHASE3
NCT00239421	COMPLETED	Pulmonary Disease, Chronic Obstructive	Boehringer Ingelheim	2003-11	PHASE4
NCT00479739	COMPLETED	Asthma	GlaxoSmithKline	2002-11	PHASE4
NCT00940329	COMPLETED	Healthy	AstraZeneca	2004-04	PHASE1
NCT00691405	COMPLETED	COPD	Sumitomo Pharma America, Inc.	2003-10	PHASE2
NCT00064402	COMPLETED	Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema	Sumitomo Pharma America, Inc.	2002-04	PHASE3
NCT00215423	COMPLETED	COPD; Chronic Obstructive Pulmonary Disease	Dey		PHASE2
NCT00215410	COMPLETED	Asthma	Dey		PHASE2
NCT00685841	COMPLETED	COPD	Sumitomo Pharma America, Inc.	2002-02	PHASE3
NCT00215384	COMPLETED	COPD	Dey		PHASE2
NCT00215397	COMPLETED	Asthma	Dey		PHASE2
NCT00215371	COMPLETED	Asthma	Dey	2002-07	PHASE2
NCT00215358	COMPLETED	Asthma	Dey	2002-07	PHASE2
NCT02238119	COMPLETED	Pulmonary Disease, Chronic Obstructive	Boehringer Ingelheim	2002-02	PHASE2
NCT02242240	COMPLETED	Pulmonary Disease, Chronic Obstructive	Boehringer Ingelheim	2001-03	PHASE2
NCT00646321	COMPLETED	Asthma	AstraZeneca	2003-04	PHASE3
NCT00652392	COMPLETED	Asthma	AstraZeneca	2003-04	PHASE3
NCT00242775	COMPLETED	Asthma	AstraZeneca	2005-05	PHASE3
NCT00288379	COMPLETED	Asthma	AstraZeneca	2004-10	PHASE3
NCT00463866	COMPLETED	Asthma	AstraZeneca	2007-03	PHASE4
NCT00418509	COMPLETED	Healthy	Novartis	2006-11	PHASE1
NCT00658255	COMPLETED	Stable Asthma	AstraZeneca	2002-10	PHASE2
NCT00280358	COMPLETED	Healthy	Dey		PHASE1
NCT00288548	UNKNOWN	Chronic Obstructive Pulmonary Disease (COPD)	Martini Hospital Groningen	2006-02	PHASE4
NCT00290264	COMPLETED	Asthma	AstraZeneca	2004-12	PHASE3
NCT00646594	COMPLETED	Asthma	AstraZeneca	2003-11	PHASE3
NCT00319306	COMPLETED	Asthma	AstraZeneca	2005-09	PHASE3
NCT00651768	COMPLETED	Asthma	AstraZeneca	2003-08	PHASE3
NCT00259779	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2005-09	PHASE3
NCT00259766	COMPLETED	Asthma	AstraZeneca	2004-04	PHASE3
NCT00646009	COMPLETED	Asthma	AstraZeneca	2003-03	PHASE3
NCT00252785	COMPLETED	Asthma	AstraZeneca	2005-10	PHASE3
NCT00490243	COMPLETED	Asthma	Medical University of Lodz	2003-07	PHASE4
NCT00646620	COMPLETED	Asthma	AstraZeneca	2003-04	PHASE3
NCT00272753	COMPLETED	Asthma	AstraZeneca	2004-04	PHASE4
NCT00394368	COMPLETED	Bronchial Asthma	Chiesi Farmaceutici S.p.A.	2004-11	PHASE3
NCT00651651	COMPLETED	Asthma	AstraZeneca	2002-08	PHASE3
NCT00561886	COMPLETED	Chronic Obstructive Pulmonary Disease	Johannes Gutenberg University Mainz	2007-04	PHASE4
NCT00646529	COMPLETED	Asthma	AstraZeneca	2002-07	PHASE3
NCT00862264	COMPLETED	Asthma	Chiesi Farmaceutici S.p.A.	2004-08	PHASE3
NCT00244608	COMPLETED	Asthma	AstraZeneca	2005-05	PHASE3
NCT00327353	COMPLETED	Asthma	GlaxoSmithKline	2004-01	PHASE4
NCT00652002	COMPLETED	Asthma	AstraZeneca	2002-07	PHASE3
NCT00239278	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2001-01	PHASE2
NCT00252824	COMPLETED	Asthma	AstraZeneca	2005-07	PHASE3
NCT00206154	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2005-04	PHASE3
NCT00379028	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2006-09	PHASE4
NCT00449501	COMPLETED	Asthma	AstraZeneca	2007-03	PHASE3
NCT00206167	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2005-04	PHASE3
NCT00646516	COMPLETED	Mild or Moderate Asthma	AstraZeneca	2003-10	PHASE3
NCT00691951	COMPLETED	Asthma	Laval University		PHASE3
NCT00326053	COMPLETED	Asthma	AstraZeneca	2006-05	PHASE3
NCT00449527	COMPLETED	Asthma	AstraZeneca	2007-03	PHASE3
NCT00385593	TERMINATED	Asthma, Bronchial	AstraZeneca	2006-09	PHASE3
NCT00422552	COMPLETED	COPD	Novartis	2006-09	PHASE1; PHASE2
NCT00252863	COMPLETED	Asthma	AstraZeneca	2004-12	PHASE3
NCT00259792	COMPLETED	Asthma	AstraZeneca	2004-09	PHASE3
NCT00421122	COMPLETED	Chronic Obstructive Pulmonary Disease	AstraZeneca	2006-09	PHASE3
NCT00651547	COMPLETED	Asthma	AstraZeneca	2002-07	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-27)

Check the Formoterol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Formoterol selectively binds to and activates beta2-adrenergic receptors on airway smooth muscle cells, triggering intracellular adenylate cyclase stimulation and subsequent cyclic AMP accumulation, which leads to protein kinase A activation and smooth muscle relaxation. This potent bronchodilatory action alleviates airway obstruction and improves pulmonary airflow, providing clinical benefit in the management of asthma and chronic obstructive pulmonary disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).